Sep 2026· International Journal of Innovative Technologies in Social Science· 0 citations· 10 references
TL;DR
Early clinical and preclinical evidence supports the feasibility of PCSK9 gene editing, and compares CRISPR-Cas9 nuclease knockout, base editing, and epigenetic silencing with established antibody and siRNA classes, focusing on efficacy, durability, and safety.
Abstract
Background: PCSK9 is a circulating protease that regulates plasma low-density lipoprotein (LDL) cholesterol levels. It binds to the LDL receptor on the surface of hepatocytes and directs the receptor toward intracellular degradation, so that greater PCSK9 activity leaves fewer LDL receptors available to clear LDL-C from the bloodstream. PCSK9 was established as a drug target largely through human genetics: naturally occurring loss-of-function variants are associated with lifelong low LDL-C and a markedly reduced risk of atherosclerotic cardiovascular disease with no apparent adverse consequences, whereas gain-of-function variants cause a severe, early onset form of familial hypercholesterolemia. Pharmacological PCSK9 inhibitors, monoclonal antibodies, and small interfering RNA (siRNAs) are currently in clinical use; however, all require repeated, lifelong administration.
Aim: This review argues that PCSK9 gene editing has progressed from a theoretical concept to an emerging therapeutic class, with three distinct technical strategies currently under active development. We compared CRISPR-Cas9 nuclease knockout, base editing, and epigenetic silencing with established antibody and siRNA classes, focusing on efficacy, durability, and safety.
Materials and Methods: A search of relevant research databases and a hand search of selected journals were conducted to identify eligible papers.
Results: Several programs based in the United States and China have demonstrated that a single dose of a gene-editing agent can lower PCSK9 and LDL-C levels in humans and animal models. Nuclease-mediated knockout and base editing produced the largest reductions, whereas epigenetic silencing produced a smaller but reversible effect. The principal safety signal identified to date was attributed to the lipid-nanoparticle delivery vehicle, rather than the editing mechanism itself.
Conclusions: Early clinical and preclinical evidence supports the feasibility of PCSK9 gene editing. The remaining gaps are long-term safety data, direct evidence of reduced cardiovascular events rather than biomarker changes alone, and a strategy for equitable access and pricing.
Activity-normalized prime editing provides a scalable framework for LDLR variant classification that substantially expands the proportion of variants with evidence for genetic diagnosis and reveals novel biology with therapeutic relevance.
P. Zhou, Minja Velimirovic, Tian Yu et al.· Circulation· 0 citations
This review examines the significant transition in cardiovascular research from conventional, wide knockout models to the utilization of advanced precision genome editing methods, particularly emphasizing CRISPR-Cas9, base editing, and prime editing.
Durlav Chowdhury, Nirdesh Singh, Swarnalata Garai et al.· European Journal of Pharmaco...· 0 citations
The potential for gene editing and epigenetic therapy for the management of dyslipidemia appears to be well tolerated, and a number of agents with the potential for robust and durable changes to atherosclerotic lipid and lipoprotein risk factors are developed.
S. Nicholls· Current Opinion in Lipidolog...· 0 citations
Statins, ezetimibe, and PCSK9 inhibitors have enabled LDL-cholesterol to be lowered to levels previously thought very hard to achieve. However, even after achieving low levels, some patients continued to have cardiovascular events, a phenomenon known as residual cardiovascular risk. This phenomenon indicates the comple...
M. Taha, Buraq Al-Ghaieb, Muntadher Al-Bulanee· American Journal of Cardiova...· 0 citations
Lipoprotein(a) [Lp(a)] is a genetically determined, apolipoprotein B-containing lipoprotein that contributes to cardiovascular risk through atherogenic, proinflammatory, and potentially antifibrinolytic mechanisms. Genetic, epidemiological, and mechanistic evidence supports a causal role for elevated Lp(a) in atheroscl...
P. Sabouret, Domenico Mario Giamundo, J. Popiołek-Kalisz et al.· Reviews in cardiovascular me...· 0 citations
High levels of "bad" cholesterol increase the risk of cardiovascular disease and are also linked to more severe COVID-19, though the reason has been unclear. We show that low-density lipoprotein (LDL) directly enhances SARS-CoV-2 RNA replication, especially in the Beta variant. The viral accessory protein ORF3a is both...
J. Hayashi, Taha Y. Taha, Irene P. Chen et al.· EMBO Reports· 0 citations
Related blog posts
MIT News · Artificial Intelligence· news.mit.eduNov 13, 2026
What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient. The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.
MIT News · Artificial Intelligence· news.mit.eduNov 12, 2026
MIT scientists developed a training method to generate models that simulate the effects of human activities on climate much more quickly than other approaches.